Renalytix (RTNXF) 6-K 30 Jun 22 Current report (foreign) Financial data

Cover Page

Cover Page	Jun. 30, 2022
Document Information [Line Items]
Document Type	6-K
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Entity Registrant Name	Renalytix plc
Entity Central Index Key	0001811115
Current Fiscal Year End Date	--06-30
Entity Address, Address Line One	Finsgate 5-7 Cranwood Street
Entity Address, City or Town	London
Entity Address, Postal Zip Code	EC1V 9EE
Entity Address, Country	GB
Entity File Number	001-39387

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Current assets:
Cash and cash equivalents	$ 32,361	$ 65,128
Accounts receivable	1,009	594
Prepaid expenses and other current assets	3,837	993
Note receivable from Kantaro	75	75
Receivable from affiliates	1	1
Total current assets	37,283	66,791
Property and equipment, net	2,850	2,490
Investment in VericiDx	4,322	9,295
Investment in Kantaro	11
Total assets	44,466	78,576
Current liabilities:
Accounts payable	2,056	1,403
Accounts payable-related party	1,007	361
Accrued expenses and other current liabilities	6,689	4,602
Accrued expenses—related party	5,031	224
Deferred revenue	67	122
Payable to affiliate—current	187	350
Total current liabilities	15,037	7,062
Other liabilities	14	53
Total liabilities	15,051	7,115
Commitments and contingencies (Note 8)
Shareholders' equity:
Ordinary shares, 0.0025 par value per share: 76,898,831 shares authorized; 72,308,930 and 72,197,286 shares issued and outstanding at March 31, 2022 and June 30, 2021, respectively	220	220
Additional paid-in capital	153,604	150,407
Accumulated other comprehensive income (loss)	3,156	8,276
Accumulated deficit	(127,565)	(87,442)
Total shareholders' equity	29,415	71,461
Total liabilities and shareholders' equity	$ 44,466	$ 78,576

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - £ / shares	Mar. 31, 2022	Jun. 30, 2021
Statement of Financial Position [Abstract]
Common stock par or stated value per share	£ 0.0025	£ 0.0025
Common stock shares authorized	76,869,831	76,869,831
Common stock shares issued	72,308,930	72,197,286
Common stock shares outstanding	72,308,930	72,197,286

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Revenue	$ 812	$ 619	$ 2,139	$ 1,019
Cost of revenue	685	169	1,404	426
Gross profit	127	450	735	593
Operating expenses:
Research and development	3,887	3,104	12,019	7,311
General and administrative	10,809	5,547	29,012	16,258
Performance of contract liability to affiliate	(32)	(130)	(163)	(889)
Total operating expenses	14,664	8,521	40,868	22,680
Loss from operations	(14,537)	(8,071)	(40,133)	(22,087)
Equity in net (losses) earnings of affiliate	(26)	(8)	11	(229)
Foreign currency /gain (loss), net	2,447	(1,095)	4,587	(8,783)
Fair value adjustment to VericiDx investment	(2,575)	337	(4,596)	5,355
Other (expense) income, net	(4)	61	8	228
Net loss	(14,695)	(8,776)	(40,123)	(25,516)
Net loss attributable to noncontrolling interest	0	0	0	611
Net loss attributable to ordinary shareholders	(14,695)	(8,776)	(40,123)	(24,905)
Other comprehensive income (loss):
Foreign exchange translation adjustment	(2,632)	1,163	(5,120)	9,504
Comprehensive loss	(17,327)	(7,613)	(45,243)	(16,012)
Comprehensive loss attributable to noncontrolling interest	0	0	0	(72)
Comprehensive loss attributable to Renalytix	$ (17,327)	$ (7,613)	$ (45,243)	$ (15,940)
Earnings Per Share, Basic	$ (0.20)	$ (0.12)	$ (0.56)	$ (0.35)
Earnings Per Share, Diluted	$ (0.20)	$ (0.12)	$ (0.56)	$ (0.35)
Weighted Average Number of Shares Outstanding, Basic	72,297,309	72,035,126	72,274,979	71,294,883
Weighted Average Number of Shares Outstanding, Diluted	72,297,309	72,035,126	72,274,979	71,294,883

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED) - USD ($)	Total	IPO [Member]	Common Stock [Member]	Common Stock [Member] IPO [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] IPO [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Accumulated Deficit [Member]	Total shareholders' (deficit) equity attributable to RenalytixAI [Member]	Total shareholders' (deficit) equity attributable to RenalytixAI [Member] IPO [Member]	Noncontrolling interests [Member]
Beginning balance at Jun. 30, 2020	$ 15,912,000		$ 179,000		$ 69,650,000		$ (1,200,000)	$ (52,717,000)	$ 15,912,000
Beginning balance, Shares at Jun. 30, 2020			59,416,134
Sale of ordinary shares, net of offering costs underwriting fees (Value)		$ 76,134,000		$ 40,000		$ 76,094,000				$ 76,134,000
Sale of ordinary shares, net of offering costs underwriting fees (Shares)				12,613,500
VericiDx distribution in specie					1,638,000		(25,000)		1,613,000		$ (1,613,000)
Stock-based compensation expense	501,000				501,000				501,000
Currency translation adjustments	2,188,000						2,255,000		2,255,000		(67,000)
Net loss	(7,614,000)							(7,221,000)	(7,221,000)		(393,000)
Ending balance at Sep. 30, 2020	87,121,000		$ 219,000		147,883,000		1,030,000	(59,938,000)	89,194,000		(2,073,000)
Ending balance, shares at Sep. 30, 2020			72,029,634
Beginning balance at Jun. 30, 2020	15,912,000		$ 179,000		69,650,000		(1,200,000)	(52,717,000)	15,912,000
Beginning balance, Shares at Jun. 30, 2020			59,416,134
Net loss	(25,516,000)
Ending balance at Mar. 31, 2021	80,026,000		$ 219,000		149,150,000		8,279,000	(77,622,000)	80,026,000		0
Ending balance, shares at Mar. 31, 2021			72,047,286
Beginning balance at Sep. 30, 2020	87,121,000		$ 219,000		147,883,000		1,030,000	(59,938,000)	89,194,000		(2,073,000)
Beginning balance, Shares at Sep. 30, 2020			72,029,634
VericiDx noncontrolling interest upon deconsolidation	2,296,000										2,296,000
Stock-based compensation expense	525,000				525,000				525,000
Currency translation adjustments	6,081,000						6,086,000		6,086,000		(5,000)
Net loss	(9,126,000)						0	(8,908,000)	(8,908,000)		(218,000)
Ending balance at Dec. 31, 2020	86,897,000		$ 219,000		148,408,000		7,116,000	(68,846,000)	86,897,000
Ending balance, shares at Dec. 31, 2020			72,029,634
Shares issued under the employee share purchase plan (Value)	111,000				111,000				111,000
Shares issued under the employee share purchase plan (Shares)			17,652
Stock-based compensation expense	631,000				631,000				631,000
Currency translation adjustments	1,163,000						1,163,000		1,163,000
Net loss	(8,776,000)							(8,776,000)	(8,776,000)
Ending balance at Mar. 31, 2021	80,026,000		$ 219,000		149,150,000		8,279,000	(77,622,000)	$ 80,026,000		$ 0
Ending balance, shares at Mar. 31, 2021			72,047,286
Beginning balance at Jun. 30, 2021	71,461,000		$ 220,000		150,407,000		8,276,000	(87,442,000)
Beginning balance, Shares at Jun. 30, 2021			72,197,286
Shares issued under the employee share purchase plan (Value)	120,000				120,000
Shares issued under the employee share purchase plan (Shares)			10,920
Stock-based compensation expense	997,000				997,000
Exercise of stock options (Value)	86,000				86,000
Exercise of stock options (Shares)			32,500
Currency translation adjustments	(2,585,000)						(2,585,000)
Net loss	(10,106,000)						0	(10,106,000)
Ending balance at Sep. 30, 2021	59,973,000		$ 220,000		151,610,000		5,691,000	(97,548,000)
Ending balance, shares at Sep. 30, 2021			72,240,706
Beginning balance at Jun. 30, 2021	$ 71,461,000		$ 220,000		150,407,000		8,276,000	(87,442,000)
Beginning balance, Shares at Jun. 30, 2021			72,197,286
Exercise of stock options (Shares)	100,724
Net loss	$ (40,123,000)
Ending balance at Mar. 31, 2022	29,415,000		$ 220,000		153,604,000		3,156,000	(127,565,000)
Ending balance, shares at Mar. 31, 2022			72,308,930
Beginning balance at Sep. 30, 2021	59,973,000		$ 220,000		151,610,000		5,691,000	(97,548,000)
Beginning balance, Shares at Sep. 30, 2021			72,240,706
Stock-based compensation expense	941,000				941,000
Exercise of stock options (Value)	111,000				111,000
Exercise of stock options (Shares)			68,224
Currency translation adjustments	97,000						97,000
Net loss	(15,322,000)							(15,322,000)
Ending balance at Dec. 31, 2021	45,800,000		$ 220,000		152,662,000		5,788,000	(112,870,000)
Ending balance, shares at Dec. 31, 2021			72,308,930
Stock-based compensation expense	942,000				942,000
Exercise of stock options (Value)					0
Currency translation adjustments	(2,632,000)						(2,632,000)
Net loss	(14,695,000)							(14,695,000)
Ending balance at Mar. 31, 2022	$ 29,415,000		$ 220,000		$ 153,604,000		$ 3,156,000	$ (127,565,000)
Ending balance, shares at Mar. 31, 2022			72,308,930

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (UNAUDITED) (Parenthetical) $ in Thousands	3 Months Ended
	Sep. 30, 2020 USD ($)
IPO [Member]
Payment of stock issuance costs	$ 9,007

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (40,123)	$ (25,516)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on VericiDx deconsolidation	0	(46)
Depreciation and amortization	354	182
Share-based compensation	2,880	1,657
Realized gain on short-term investments	0	(18)
Equity in (net earnings) losses of affiliate	(11)	229
Fair value adjustment to VericiDx investment	4,596	(5,355)
Unrealized foreign exchange loss (gain) loss	(4,169)	5,546
Changes in operating assets and liabilities:
Accounts receivable	(415)	(68)
Prepaid expenses and other current assets	(2,915)	(1,951)
Receivable from affiliates	0	(143)
Accounts payable	673	240
Accounts payable - related party	646	0
Accrued expenses and other current liabilities	2,091	2,491
Accrued expenses—related party	4,893	287
Deferred revenue	(55)	0
Payable to affiliate - current	(163)	(890)
Other liabilities	(39)	53
Net cash used in operating activities	(31,757)	(23,302)
Cash flows from investing activities:
Purchases of property and equipment	(619)	(879)
Software development costs	(103)	(428)
Proceeds from short-term investments	0	1,000
Note receivable - related party	0	(167)
Decrease in cash (VericiDx deconsolidation)	0	(62)
Net cash used in investing activities	(722)	(536)
Cash flows from financing activities:
Gross proceeds from the issuance of ordinary shares, net of underwriting fees	0	79,182
Payment of offering costs	0	(2,305)
Proceeds from the issuance of ordinary shares under employee share purchase plan	120	111
Proceeds from exercise of stock options	197	0
Net cash provided by financing activities	317	76,988
Effect of exchange rate changes on cash	(605)	3,633
Net (decrease) increase in cash and cash equivalents	(32,767)	56,783
Cash and cash equivalents, beginning of period	65,128	13,293
Cash and cash equivalents, end of period	32,361	70,076
Supplemental noncash investing and financing activities:
Deemed distribution of VericiDx ordinary shares	0	75
Conversion of distribution of VericiDx note receivable into VericiDx ordinary shares	0	2,556
Software development costs in accounts payable and accrued expenses	0	195
Purchase of property and equipment in accounts payable and accrued expenses	$ 50	$ 31

Business and risks

Business and risks	9 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business and risks	1. Business and risks Renalytix and its wholly-owned subsidiaries, Renalytix AI, Inc. and Renalytix AI Limited (collectively, “Renalytix”, or the “Company”) is an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient outcomes and significantly lower healthcare costs. KidneyIntelX, the Company’s first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from EHR systems, to generate a unique patient risk score. Additionally, the Company has successfully completed the first stage of a statement of work with AstraZeneca Pharmaceuticals LP (“AstraZeneca”) to conduct a feasibility study to determine the impact of the use of the Company’s KidneyIntelX platform to optimize utilization of various CKD agents. Further, in December 2020 the Company entered into a master service agreement with AstraZeneca for future services of this nature. As a result of the initial success with AstraZeneca the Company plans to pursue further collaborations with pharmaceutical companies and make ‘Pharmaceutical Services Revenue’ a core part of the business going forward with the goal of improving guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software. Since inception in March 2018, the Company has focused primarily on organizing and staffing the Company, raising capital, developing the KidneyIntelX platform, conducting clinical validation studies for KidneyIntelX, establishing and protecting its intellectual property portfolio and commercial laboratory operations, pursuing regulatory clearance and developing a reimbursement strategy. To date, the Company has generated de minimis revenue from the sales of KidneyIntelX tests. The Company has funded its operations primarily through equity and debt financings. The Company is subject to risks and uncertainties common to early-stage companies in the diagnostics industry, including, but not limited to, ability to secure additional capital to fund operations, compliance with governmental regulations, development by competitors of new technological innovations, dependence on key personnel and protection of proprietary technology. To achieve widespread usage, KidneyIntelX and additional diagnostic products currently under development will require extensive clinical testing and validation prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities .

Liquidity and Going Concern

Liquidity and Going Concern	9 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Going Concern	2. Liquidity and Going Concern The Company has incurred recurring losses and negative cash flows from operations since inception and had an accumulated deficit of $ 127.6 million as of March 31, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales of KidneyIntelX or any future products currently in development. Management believes its cash and cash equivalents of $ 32.4 million as of March 31, 2022 together with the aggregate $ 26.8 million of gross proceeds raised in April 2022, are sufficient to fund the projected operations for at least the next twelve months from the issuance date of these financial statements. Substantial additional capital will be needed by the Company to fund its operations, expand its commercial activities and develop other potential diagnostic related products. The Company plans to seek additional funding through public or private equity offerings, debt financings, other collaborations, strategic alliances, and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company’s shareholders. If the Company is unable to obtain funding, the Company could be required to delay, curtail or discontinue research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.

Basis of presentation and summa

Basis of presentation and summary of significant accounting policies	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Basis of presentation and summary of significant accounting policies	3. Basis of presentation and summary of significant accounting policies The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). In the opinion of management, the accompanying unaudited interim condensed consolidated financial statements include all normal and recurring adjustments (which consist primarily of accruals and estimates that impact the financial statements) considered necessary to present fairly the Company’s financial position as of March 31, 2022 and its results of operations for the three and nine months ended March 31, 2022 and 2021 and cash flows for the nine months ended March 31, 2022 and 2021. Operating results for the three and nine months ended March 31, 2022, are not necessarily indicative of the results that may be expected for the year ending June 30, 2022. The unaudited interim condensed consolidated financial statements, presented herein, do not contain the required disclosures under U.S. GAAP for annual financial statements. The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended June 30, 2021. Principles of consolidation The unaudited interim condensed consolidated financial statements include the accounts of Renalytix plc, and its wholly-owned subsidiaries, Renalytix AI, Inc. and Renalytix AI Limited. All inter-company balances and transactions have been eliminated in consolidation. The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting. Use of estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimate include the assumptions used in determining the fair value of share-based awards, recording the prepaid/accrual and associated expense for research and development activities performed for the Company by third parties, determining useful lives of property and equipment and capitalized software, the assessment of noncontrolling interest and equity method investments, fair value measurements (including those related to VericiDx), the payable to affiliates and the consolidation and deconsolidation of variable interest entities. Segment information The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Foreign currency The Company’s condensed consolidated financial statements are presented in U.S. dollars, the reporting currency of the Company. The functional currency of Renalytix plc and Renalytix AI Limited is GB Pounds. The functional currency of Renalytix AI, Inc. is the U.S. dollar. Assets and liabilities of Renalytix plc and Renalytix AI Limited are translated at the rate of exchange at period-end, while the statements of operations are translated at the weighted average exchange rates in effect during the reporting period. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the functional currency are included in income in the period in which the change occurs and reported in the consolidated statements of operations and comprehensive loss . Concentrations of credit risk and major customers Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable balances. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and are not exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships and has not experienced any losses on such accounts. The Company’s accounts receivable are derived from revenue earned from customers located in the U.S. All of the Company’s revenue has been generated from four customers for the nine months ended March 31, 2022, and two customer for the nine months ended March 31, 2021. The Company performs initial and ongoing credit reviews on customers, which involve consideration of the customers’ financial information, their location, and other factors to assess the customers’ ability to pay . Fair value of financial instruments At March 31, 2022 and June 30, 2021 , the Company’s financial instruments included accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. The carrying amounts of these assets and liabilities approximates fair value due to their short-term nature. Fair value option Under the Fair Value Option Subsections of ASC subtopic 825-10, Financial Instruments – Overall , the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument-by-instrument basis, with changes in fair value reported in earnings (see Note 5). Cash and cash equivalents The Company considers all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. As of March 31, 2022, the Company had a cash balance of $ 32.4 million. As of June 30, 2021, the Company had a cash balance of $ 65.1 million. Accounts receivable Accounts receivable are recorded at the invoice amount and are non-interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reserves specific receivables if collectability is no longer reasonably assured. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations, historical payment patterns, and individual customer circumstances. No reserves have been recorded as of March 31, 2022 or June 30, 2021 . Property and equipment Property and equipment are recorded at cost. Depreciation is determined using the straight-line method over the estimated useful lives ranging from three to ten years. Expenditures for maintenance and repairs are expensed as incurred while renewals and betterments are capitalized. When property and equipment are sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in operations. Performance of contract liability to affiliate In May 2020, the Company and the Icahn School of Medicine at Mount Sinai entered into an operating agreement (“Kantaro Operating Agreement”) to form a joint venture, Kantaro Biosciences LLC (“Kantaro”), for the purpose of developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2 originally developed by Mount Sinai. Kantaro has partnered with Bio-Techne Corporation to develop and launch the new test which is designed for use in any authorized clinical testing laboratory without the need for proprietary equipment. During the three and nine months ended March 31, 2022 , the Company recognized $ 0.03 million and $ 0.16 million, respectively, related to the performance of the contract liability with Kantaro. During the three and nine months ended March 31, 2021 , the Company recognized $ 0.13 million and $ 0.89 million, respectively, related to the performance of the contract liability with Kantaro. This represents the allocation of costs for performing services on behalf of Kantaro. Equity method investments The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company’s share of equity in the earnings of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. Kantaro Biosciences LLC As the Company can exert significant influence over, but does not control, Kantaro’s operations through voting rights or representation on Kantaro’s board of directors, the Company accounts for this investment using the equity method of accounting. The Company records its share in Kantaro’s earnings and losses in the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value. The Company owned 25 % of the membership equity units in Kantaro at March 31, 2022 and June 30, 2021. VericiDx Limited As the Company can exert significant influence over, but does not control, VericiDx’s operations through representation on VericiDx’s board of directors, the Company accounts for this investment as an equity method investment and has elected the fair value option because VericiDx’s stock price is readily observable via the London Stock Exchange. Under the fair value option, the investment in VericiDx is recorded at fair value at each reporting period with subsequent changes in fair value reported in the condensed consolidated statements of operations and comprehensive loss. Based on closing stock price of VericiDx, the fair value of the investment in VericiDx was $ 4.3 million at March 31, 2022 and $ 9.3 million at June 30, 2021. During the three and nine months ended March 31, 2022 , the Company recorded a fair value adjustment of $( 2.6 ) million and $( 4.6 ) million, respectively, in the condensed consolidated statements of operations and comprehensive loss. During each of the three and nine months ended March 31, 2021 , the Company recorded a fair value adjustment of $ 0.3 million and $ 5.4 million in the condensed consolidated statements of operations and comprehensive loss. The Company owned 5.8 % of the ordinary shares of VericiDx at March 31, 2022 and 6.9 % of the ordinary shares of VericiDx at June 30, 2021 . Impairment assessment The Company evaluates its investments that are in unrealized loss positions, if any, and equity method investments for other-than-temporary impairment on a quarterly basis (see Note 5). Such evaluation involves a variety of considerations, including assessments of the risks and uncertainties associated with general economic conditions and distinct conditions affecting specific issuers or investees. Factors considered by the Company include (i) the length of time and the extent to which an investment’s fair value has been below its cost; (ii) the financial condition, credit worthiness, and near-term prospects of the issuer; (iii) the length of time to maturity; (iv) future economic conditions and market forecasts; (v) the Company’s intent and ability to retain its investment for a period of time sufficient to allow for recovery of market value; (vi) an assessment of whether it is more likely than not that the Company will be required to sell its investment before recovery of market value; and (vii) whether events or changes in circumstances indicate that the investment’s carrying amount might not be recoverable. Software development costs The Company follows the provisions of ASC 985, Software, which requires software development costs for software to be marketed externally to be expensed as incurred until the establishment of technological feasibility, at which time those costs are capitalized until the software is available for general release and amortized over its estimated useful life of ten years. Technological feasibility is established upon the completion of a working model that has been validated. Revenue recognition The Company accounts for revenue under ASC 606 – Revenue from Contracts with Customers (“ASC 606”). Pursuant to ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. Certain contracts have options for the customer to acquire additional services. The Company evaluates these options to determine if a material right exists. If, after that evaluation, it determines a material right does exist, it assigns value to the material right based upon the renewal option approach. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. The Company uses present right to payment and customer acceptance as indicators to determine the transfer of control to the customer occurs at a point in time. Sales tax and other similar taxes are excluded from revenues . Cost of revenue Cost of revenue consists of costs directly attributable to the services rendered, including labor costs and lab consumables directly related to revenue generating activities. Research and development expenses Research and development costs consist primarily of costs incurred in connection with the development of KidneyIntelX and other studies for KidneyIntelX to determine clinical value and performance in different CKD populations. Research and development costs are expensed as incurred. Share-based compensation The Company measures equity classified share-based awards granted to employees and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is the vesting period of the respective award. The Company accounts for forfeitures as they occur. For share-based awards with service-based vesting conditions, the Company recognizes compensation expense on a straight-line basis over the service period. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield. The Company was a privately-held organization prior to November 2018 and has been a publicly-traded company for a limited period of time and therefore lacks company-specific historical and implied volatility information for its shares. Therefore, it estimates its expected share price volatility based on the historical volatility of publicly-traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is none based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future. The Company classifies share-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified. Comprehensive loss Comprehensive loss includes net loss as well as other changes in shareholders’ equity that result from transactions and economic events other than those with shareholders. For the periods presented the only other changes in shareholders’ equity is from foreign currency translation. Net loss per ordinary share Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during each period. Diluted net loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as options which would result in the issuance of incremental ordinary shares. Potentially dilutive securities outstanding as of March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive. Therefore, the weighted average number of shares used to calculate both basic and diluted net loss per share are the same. As of March 31, 2022 and 2021 , there were 4,560,901 and 3,683,858 shares, respectively, issuable upon exercise of outstanding options that were anti-dilutive and excluded from diluted loss per share for the three and nine months ended March 31, 2022 and 2021 , respectively. Emerging growth company The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). Under the JOBS Act, companies have extended transition periods available for complying with new or revised accounting standards. The Company has elected to avail itself of this exemption and, therefore, while the Company is an emerging growth company it will not be subject to new or revised accounting standards at the same time that they become applicable to other public emerging growth companies that have not elected to avail themselves of this exemption. Recently issued accounting pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02" or "Topic 842"), in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. For public companies, ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) the lease classification or (c) the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous U.S. GAAP. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. In June 2020, the FASB issued ASU No 2020-05 that further delayed the effective date of Topic 842 to fiscal years beginning after July 1, 2022, and interim periods within those years. The Company is currently evaluating the impact of adopting this guidance to its condensed consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments , which requires measurement and recognition of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This is different from the current guidance as this will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets. The new guidance will be effective for the Company on July 1, 2023. The Company is currently evaluating the impact of adopting this guidance to its consolidated financial statements. In January 2020, FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) ("ASU2021-01"), which, generally, provides guidance for investments in entities accounted for under the equity method of accounting. ASU 2020-01 is effective for all entities with fiscal years beginning after December 15, 2021, including interim periods therein. The Company is currently evaluating the impact of adopting this guidance to its consolidated financial statements.

Revenue

Revenue	9 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Revenue	4. Revenue Testing services revenue Testing services revenue is generated from the KidneyIntelX platform, which provides analytical services to customers. Each individual test is a performance obligation that is satisfied at a point in time upon completion of the testing process (when results are reported) which is when control passes to the customer and revenue is recognized. During the three and nine months ended March 31, 2022 , the Company recognized $ 0.8 million and $ 1.9 million, respectively, of testing services revenue. Sales tax and other similar taxes are excluded from revenues. During the three and nine months ended March 31, 2021 , the Company recognized $ 0.1 million and $ 0.1 million, respectively of testing services revenue. Pharmaceutical services revenue Pharmaceutical services revenue is generated from the provision of analytical services to customers. Contracts with customers generally include an initial upfront payment and additional payments upon achieving performance milestones. The Company uses present right to payment and customer acceptance as indicators to determine the transfer of control to the customer which may occur at a point in time or over time depending on the individual contract terms. Sales tax and other similar taxes are excluded from revenues. During the three and nine months ended March 31, 2022 , the Company recognized $ 0.0 million and $ 0.2 million, respectively, of pharmaceutical services revenue where performance obligations are satisfied over time. During the, the three and nine months ended March 31, 2021 Company recognized $ 0.0 million and $ 0.4 million, respectively, of pharmaceutical services revenue where performance obligations are satisfied over time. Professional services revenue Professional services revenue consists of services related to the creation of a branded care navigation portal/pathway for use with KidneyIntelX. Revenue is recognized when control of the promised services is transferred to customers and the performance obligation is fulfilled in an amount that reflects the consideration that the Company expects to be entitled in exchange for those services. The company did no t recognize any professional services revenue during the three and nine months ended March 31, 2022. During the three and nine months ended March 31, 2021 the company recognized $ 0.6 million and $ 0.6 million, respectively, of other services revenue where performance obligations are satisfied at a point in time. Deferred revenue Deferred revenue represents the allocated transaction price to the material right which will be recognized as revenue when the renewal options are exercised which is expected to occur over the next 21 months. The following table summarizes the changes in deferred revenue: March 31, 2022 June 30, 2021 Balance, beginning of period $ 122 $ — Deferral of revenue 67 250 Revenue recognized ( 122 ) ( 128 ) Balance, end of period $ 67 $ 122

Fair value measurements and the

Fair value measurements and the fair value option	9 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Fair value measurements and the fair value option	5. Fair value measurements and the fair value option Assets and liabilities recorded at fair value on a recurring basis in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure their fair values. Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The authoritative guidance on fair value measurements establishes a three-tier fair value hierarchy for disclosure of fair value measurements as follows: • Level 1 - Quoted prices (unadjusted in active markets for identical assets or liabilities) • Level 2 - Inputs other than quoted prices in active markets that are observable either directly or indirectly • Level 3 - Unobservable inputs in which there is little or no market data, which require the Company to develop its own assumptions This hierarchy requires the use of observable market data when available and to minimize the use of unobservable inputs when determining fair value. The following fair value hierarchy table presents information about the Company’s assets measured at fair value on a recurring basis: Fair value measurement at reporting date using (in thousands) (Level 1) (Level 2) (Level 3) March 31, 2022 Assets: Equity investment in VericiDx $ 4,322 $ — $ — June 30, 2021 Assets: Equity investment in VericiDx $ 9,295 $ — $ — Non-financial assets and liabilities The Company’s non-financial assets, which primarily consist of property and equipment and equity method investments, are not required to be measured at fair value on a recurring basis, and instead are reported at carrying value in its condensed consolidated balance sheet. However, on a periodic basis or whenever events or changes in circumstances indicate that they may not be fully recoverable, the respective carrying value of non-financial assets are assessed for impairment and, if ultimately considered impaired, are adjusted and written down to their fair value, as estimated based on consideration of external market participant assumptions. Based on sales forecasts, the Company concluded that its equity method investment in Kantaro was impaired due to a shift in focus from COVID antibody testing to promoting vaccination in the United States and European Union. As a result of this shift, demand for COVID antibody testing decreased. The forecasts indicate there is a prolonged period of time that Kantaro’s fair value is below the carrying value of the investment and the discounted and undiscounted cash flows are also below the carrying value of the investment. For these reasons, the Company concluded the decline in value is other-than-temporary. As such, during the year ended June 30, 2021, the Company determined the fair value using a discounted cash flow model and concluded that the fair value of the equity method investment in Kantaro was zero .

Property and equipment

Property and equipment	9 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Property and equipment	6. Property and equipment Property and equipment consists of (in thousands): March 31, 2022 June 30, 2021 Lab equipment $ 1,144 $ 592 Software 1,574 1,534 Office equipment 121 84 Office furniture 35 35 Leasehold improvements 576 576 Construction in progress 79 — Total 3,529 2,821 Less accumulated depreciation and amortization ( 679 ) ( 331 ) $ 2,850 $ 2,490 Depreciation expense was $ 0.1 million and $ 0.2 million for the three and nine months ended March 31, 2022 , respectively. Depreciation expense was $ 0.05 million and $ 0.1 million for the three and nine months ended March 31, 2021, respectively. As of March 31, 2022 and June 30, 2021, there was $ 1.1 million and $ 1.3 million, respectively, of unamortized capitalized software development costs. Amortization expense related to capitalized software development costs was $ 0.03 million and $ 0.1 million for the three and nine months ended March 31, 2022 , respectively. Amortization expense related to capitalized software development costs was $ 0.03 million and $ 0.05 million for the three and nine months ended March 31, 2021, respectively. As of March 31, 2022, the expected amortization expense for software for the next five years and thereafter is as follows: 2022 (remaining three months) $ 33 2023 130 2024 130 2025 130 2026 130 Thereafter 567 $ 1,120

Accrued expenses and other curr

Accrued expenses and other current liabilities	9 Months Ended
	Mar. 31, 2022
Accounts Payable and Accrued Liabilities, Current [Abstract]
Accrued expenses and other current liabilities	7. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of (in thousands): March 31, 2022 June 30, 2021 Consulting and professional fees $ 328 $ 954 Research and development 875 — Payroll and related benefits 4,701 3,493 Deferred offering 504 — Other 281 155 $ 6,689 $ 4,602

Commitments and contingencies

Commitments and contingencies	9 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and contingencies	8. Commitments and contingencies Leases The Company entered into operating lease agreements for office space and laboratory testing facilities with terms ranging from month-to-month to five years . During the three and nine months ended March 31, 2022 , the Company recognized rent expense of $ 0.1 million and $ 0.3 million, respectively. During the three and nine months ended March 31, 2021 , the Company recognized rent expense of $ 0.1 million and $ 0.3 million, respectively, related to all leases. The future minimum payments for noncancelable leases with terms in excess of one year for each fiscal year are as follows (in thousands): 2022 (remaining three months) $ 33 2023 134 2024 138 2025 46 2026 — Thereafter — Total $ 351 DaVita Inc . In January 2021, the Company entered into a Master Care Coordination Services Agreement with DaVita Inc. (“DaVita”) whereby DaVita agreed to provide certain care coordination services to covered patients as requested by the Company ("Care Coordination Services"), with those covered patients identified by the Company’s KidneyIntelX diagnostic and subject to insurance coverage ("Covered Patients"). Those covered patients may also be included in connection with various clinical research studies or quality improvement initiatives (each a “Study”). Both parties agreed to establish a joint steering committee to oversee the care coordination services and exchange and evaluate results of each Study. The Company will pay DaVita a monthly fixed fee based on the number of covered patients. The initial term of the agreement is three years with successive one-year renewals upon written mutual agreement of both parties. For the Care Coordination Services furnished by DaVita (or an affiliate of DaVita) under the terms of a statement of work, the Company shall pay DaVita (or such affiliate of DaVita) a monthly payment of (a) $ 10.00 in respect of Care Coordination Services multiplied by the number of Covered Patients, plus (b) $ 3.50 , in respect of patient engagement services, multiplied by the number of Covered Patients. No expenses were recorded in the periods related to this agreement. Employment agreements The Company has entered into employment agreements with certain key executives providing for compensation and severance in certain circumstances, as set forth in the agreements. Retirement plans The Company maintains a defined contribution 401(k) retirement plan which covers all U.S. employees. Employees are eligible after three months of service. Under the 401(k) plan, participating employees may make contributions in an amount up to the limit set by the Internal Revenue Service on an annual basis. The Company has a safe harbor plan and makes contributions to employee accounts of 5 % of compensation (as defined by the plan). The Company contributed $ 0.1 million and $ 0.3 million for the three and nine months ended March 31, 2022 , respectively, and the Company contributed $ 0.05 million and $ 0.1 million for the three and nine months ended March 31, 2021, respectively. Legal proceedings The Company is not a party to any litigation and does not have contingency reserves established for any litigation liabilities. At each reporting date, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies.

License and services agreements

License and services agreements	9 Months Ended
	Mar. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
License and services agreements	9. License and services agreements Mount Sinai license and sponsored research agreements On May 30, 2018, the Company entered into an exclusive license agreement (the “ISMMS License Agreement”) and, on March 7, 2019, a sponsored research agreement (the “ISMMS SRA”) with Mount Sinai. Under the terms of the ISMMS License Agreement, ISMMS granted the Company (i) an exclusive, sublicensable license to use certain patent rights covering specific inventions concerning the utilization of biomarkers guided artificial intelligence techniques for detecting kidney functional decline (the “ISMMS Technology”), (ii) a non-exclusive license under unregistered licensed copyrights and licensed know-how and (iii) an exclusive option to obtain licensed technology conceived after May 30, 2018. The Company is obligated to pay Mount Sinai $ 1.5 million and $ 7.5 million in commercial milestone payments upon achieving worldwide net sales of KidneyIntelX of $ 50.0 million and $ 300.0 million, respectively. The Company is also obligated to pay Mount Sinai a 4 % to 5 % royalty on net sales of KidneyIntelX, subject to customary reductions. Royalties are payable on a product-by-product basis from first commercial sale of such product until the later of (1) expiration of the last valid claim of a licensed patent covering such product or (2) on a country-by-country basis, 12 years from first commercial sale of such product in such country. Moreover, the Company is obligated to pay Mount Sinai between 15 % and 25 % of any consideration received from a sublicensee. Furthermore, the Company agreed to carry out and fund a clinical utility study for KidneyIntelX at an estimated cost of $ 0.7 million. As part of the ISMMS SRA, the Company has agreed to fund several research projects to further develop the ISMMS Technology. The Company incurred no expenses under the ISMMS SRA for the three months ended March 31, 2022 and $ 0.4 million in research and development expenses under the ISMMS SRA for the nine months ended March 31, 2022 . The Company incurred $ 0.03 million and $ 0.3 million in research and development expenses under the ISMMS SRA for the three and nine months ended March 31, 2021, respectively. Mount Sinai COVID-19 sponsored research agreement In August 2020, and as amended in December 2020, the Company entered into a Multi-center Assessment of Survivors for Kidney Disease after COVID-19 Study (the “MASKeD-COVID Study”) with ISMMS. This study involves multiple major academic institutions, including Mount Sinai, University of Michigan, Johns Hopkins, Yale University and Rutgers University. The goal of this study is to understand the long-term kidney epidemiology of CKD in survivors of COVID-19 and validate KidneyIntelX for prediction of long-term kidney outcomes post-COVID hospitalization that will inform further prevention, treatment and clinical care. Under the terms of the MASKeD-COVID Study, the Company is obligated to pay for all direct and indirect costs incurred under the sponsored research agreement in an amount totaling $ 1.8 million. As of March 31, 2022 , amounts due to ISMMS under the MASKeD-COVID Study totaled $ 1.0 million. No expenses were recorded during the three months ended March 31, 2022 and $ 0.6 million was expensed during the nine months ended March 31, 2022 . The Company did no t incur any expenses related to this program during the three and nine months ended March 31, 2021. Joslin diabetes center agreement In October 2018, the Company purchased a worldwide exclusive license agreement (the “Joslin Agreement”) with the Joslin Diabetes Center, Inc. (“Joslin”) that was previously entered into with EKF Diagnostics Holding Plc (“EKF”), a related party, in July 2017. The license agreement provides the Company with the right to develop and commercialize licensed products covering a novel methodology of diagnosing and predicting kidney disease using certain biomarkers (the “Joslin Diabetes Technology”). Under the terms of the Joslin Agreement, the Company is obligated to pay Joslin aggregate commercial milestone payments of $ 0.3 million and $ 1.0 million in commercial milestone payments upon achieving worldwide net sales of licensed products and processes of $ 2.0 million and $ 10.0 million, respectively. The Company is also obligated to pay Joslin a 5 % royalty on net sales of any licensed products or licensed processes, subject to customary reductions. The company accrued $ 0.1 million of royalties due to Joslin as of March 31, 2022 . Moreover, the Company is obligated to pay Joslin 25 % of any consideration received from a sublicensee. The Joslin Agreement initially expires on July 31, 2025 and is subject to an automatic five-year extension unless either party notifies the other party of its intent not to extend the agreement at least 180 days prior to initial expiration. Either party may terminate the Joslin Agreement earlier upon an uncured material breach of the agreement by the other party, the insolvency of the other party, or in the event the other party is unable to perform its obligations under the agreement for a specified period. Additionally, Joslin may terminate the agreement in the event that the Company ceases developing or commercializing licensed products or processes, if the Company fails to maintain certain required insurance policies, and if the Company fails to pay patent expenses related to the licensed patents.

Shareholders' equity

Shareholders' equity	9 Months Ended
	Mar. 31, 2022
Stockholders' Equity Note [Abstract]
Shareholders' equity	10. Shareholders’ equity Ordinary shares As of March 31, 2022 , the Company had 76,869,831 ordinary shares authorized on a fully diluted basis. Each share entitles the holder to one vote on all matters submitted to a vote of the Company’s shareholders. Ordinary shareholders are entitled to receive dividends as may be declared by the board of directors. From inception through March 31, 2022 , no cash dividends have been declared or paid.

Share-based compensation

Share-based compensation	9 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Share-based compensation	11. Share-based compensation Equity Incentive Plans In November 2018, Company established the Renalytix plc Share Option Plan (the “Plan”) and a U.S. Sub-Plan and Non-Employee Sub-Plan. The Plans provide for the Company to grant options, restricted share awards and other share-based awards to employees, directors and consultants of the Company. As of March 31, 2022 , there were 2,642,062 shares available for future issuance under the Plans. The Plans are administered by the board of directors. The exercise prices, vesting and other restrictions are determined at their discretion, except that all options granted have exercise prices equal to the fair value of the underlying ordinary shares on the date of the grant and the term of stock option may not be greater than ten years from the grant date. The options granted as of March 31, 2022 vest equally over twelve quarters following the grant date, with the exception of 80,724 options which vested immediately when granted, 1,077,100 options which vest 25 % on the one year anniversary and equally over twelve quarters following the one year anniversary and 500,000 which vest 1/12 th on the commencement date and equally over twelve quarters following the one year anniversary . If options remain unexercised after the date one day before the tenth anniversary of grant, the options expire. On termination of employment, any options that remain unexercised are either forfeited immediately or after a delayed expiration period, depending on the circumstances of termination. Upon the exercise of awards, new ordinary shares are issued by the Company. The Company recorded share-based compensation expense in the following expense categories in the condensed consolidated statements of operations for the three and nine months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, Nine Months Ended March 31, 2022 2021 2022 2021 Research and development $ 78 $ 237 $ 378 $ 631 General and administrative 845 374 2,432 973 $ 923 $ 611 $ 2,810 $ 1,604 The fair value of options is estimated using the Black-Scholes option pricing model, which takes into account inputs such as the exercise price, the value of the underlying ordinary shares at the grant date, expected term, expected volatility, risk-free interest rate and dividend yield. The fair value of each grant of options during the nine months ended March 31, 2022 and 2021 were determined using the methods and assumptions discussed below. o The expected term of employee options is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin No. 107, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data. o The expected volatility is based on historical volatility of the publicly-traded common stock of a peer group of companies. o The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term. o The expected dividend yield is none because the Company has not historically paid and does not expect for the foreseeable future to pay a dividend on its ordinary shares. For the nine months ended March 31, 2022 and 2021, the grant date fair value of all option grants was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions: Nine Months Ended March 31, 2022 2021 Expected term (in years) 6.0 5.8 Expected volatility 65.77 % 67.10 % Risk-free rate 1.43 % 0.50 % Dividend yield — % — % The weighted average fair value of the options granted during the nine months ended March 31, 2022 and 2021 was $ 6.02 and $ 4.51 per share, respectively. The following table summarizes the stock option granted to employees and non-employees for the nine months ended March 31, 2022: Number of Weighted- Weighted- Outstanding at June 30, 2021 4,265,958 $ 4.73 8.2 Granted 515,000 $ 10.06 Exercised ( 100,724 ) $ 1.89 Forfeited ( 119,333 ) $ 6.67 Outstanding at March 31, 2022 4,560,901 $ 4.99 8.7 Exercisable at March 31, 2022 3,213,850 $ 3.44 8.1 Vested at March 31, 2022 4,560,901 $ 4.99 8.7 As of March 31, 2022 , there was $ 8.1 million in unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted average period of 1.91 years. The aggregate intrinsic value of options outstanding and options exercisable at March 31, 2022 was $ 4.4 million and $ 4.4 million, respectively. Employee Share Purchase Plan The Company’s 2020 Employee Share Purchase Plan (the “ESPP”) became effective on August 17, 2020. The ESPP authorizes the issuance of up to 850,000 shares of the Company’s common stock. The number of shares of the Company’s common stock that may be issued pursuant to rights granted under the ESPP shall automatically increase on January 1st of each year, commencing on January 1, 2021 and continuing for ten years , in an amount equal to the lesser of one percent of the total number of shares of the Company’s common stock outstanding on December 31st of the preceding calendar year, and 2,000,000 ordinary shares, subject to the discretion of the board of directors or remuneration committee to determine a lesser number of shares shall be added for such year. Under the ESPP, eligible employees can purchase the Company’s common stock through accumulated payroll deductions at such times as are established by the board of directors or remuneration committee. Eligible employees may purchase the Company’s common stock at 85 % of the lower of the fair market value of the Company’s common stock on the first day of the offering period or on the purchase date. Eligible employees may contribute up to 15 % of their eligible compensation. Under the ESPP, a participant may not purchase more than $ 25,000 worth of the Company’s common stock for each calendar year in which such rights is outstanding. During the nine months ended March 31, 2022 , 10,920 shares were purchased under the ESPP. In accordance with the guidance in ASC 718-50 – Compensation – Stock Compensation , the ability to purchase shares of the Company’s common stock at 85% of the lower of the price on the first day of the offering period or the last day of the offering period (i.e. the purchase date) represents an option and, therefore, the ESPP is a compensatory plan under this guidance. Accordingly, share-based compensation expense is determined based on the option’s grant-date fair value as estimated by applying the Black Scholes option-pricing model and is recognized over the withholding period. The Company recognized share-based compensation expense of $ 0.2 million and $ 0.07 million during the three and nine months ended March 31, 2022 , respectively, and $ 0.02 million and $ 0.05 million during the three and nine months ended March 31, 2021 , respectively, related to the ESPP.

Related-party transactions

Related-party transactions	9 Months Ended
	Mar. 31, 2022
Related Party Transactions [Abstract]
Related-party transactions	12. Related-party transactions EKF Diagnostic Holdings During the three and nine months ended March 31, 2022 , the Company incurred expenses of $ 0.1 million and $ 0.2 million, respectively, related to employees of EKF who provided services to Renalytix and this amount is included in general and administrative expenses in the condensed consolidated statements of operations. During the three and nine months ended March 31, 2021 , the Company incurred expenses of $ 0.1 million and $ 0.1 million, respectively, related to employees of EKF who provided services to Renalytix and this amount is included in general and administrative expenses in the condensed consolidated statements of operations. Icahn School of Medicine at Mount Sinai In May 2018, the Company secured its cornerstone license agreement with the Icahn School of Medicine at Mount Sinai ("ISMMS") for research and clinical study work and intended commercialization by the Company (see Note 9). As part of the collaboration, ISMMS became a shareholder in the Company and has subsequently made equity investments both in the Company’s IPO on AIM in November 2018, the subsequent sale of ordinary shares in July 2019 and the Company’s IPO on Nasdaq in July 2020. As of March 31, 2022 , amounts due to ISMMS totaled $ 2.1 million and are included within accrued expenses and other current liabilities and accounts payable on the balance sheet. During the three and nine months ended March 31, 2022, the Company incurred expense s of $ 0.2 million and $ 2.9 milli on, respectively, which are included in research and development expenses in the condensed consolidated statement of operations. During the three and nine months ended March 31, 2021 , the Company incurred expenses of $ 0.2 million and $ 0.5 million, respectively, which are included in research and development expenses in the condensed consolidated statement of operations. On March 31, 2022, the Company announced a financing package which included a $ 4.0 million dollar equity investment by ISMMS. At the time of the deal announcement and prior to completion of the financing transaction, the Company received $ 4.0 million in funds from ISMMS which were recorded as a $ 4.0 million current liability due to ISMMS, which is to be satisfied upon successful completion of the financing transaction and issuance of equity in April 2022, as noted in Note 13. Kantaro Biosciences LLC In connection with the formation of Kantaro, the Company entered into a five-year Advisory Services Agreement (“Advisory Agreement”) pursuant to which the Company has agreed to provide certain advisory services to Kantaro. Pursuant to the Kantaro Operating Agreement, Kantaro issued 750 Class A Units to Mount Sinai in exchange for Mount Sinai granting licenses to Kantaro under certain intellectual property rights of Mount Sinai and 250 Class A Units to the Company as the sole consideration for the services to be rendered by the Company under the Advisory Agreement. A portion of the Company’s units are subject to forfeiture if, prior to December 31, 2021, Kantaro terminates the Advisory Agreement as a result of an uncured material breach of the Advisory Agreement or in the event the Company is acquired by a hospital or health system that serves all or any portion of the service areas served by Mount Sinai. The Company determined the fair value of the services to be provided under the Advisory Agreement was $ 2.0 million and the fair value of the Class A units received from Kantaro was $ 2.0 million. Fair value was determined using discounted cash flows which is a Level 3 measurement in the fair value hierarchy. The method requires several judgments and assumptions which include discount rates and future cash flows, among others. As a result of the prior year impairment charge discussed in Note 5, the carrying value of the Kantaro investment was written down to zero . A contributing factor to the impairment consideration for Kantaro was lower forecasted sales volume and consequently, a lower time commitment from Renalytix employees. Based on these circumstances, the Company adjusted the liability to perform services to Kantaro under the Advisory Agreement during the year ended June 30, 2021. As of March 31, 2022 , the total liability associated with the services was $ 0.2 million, of which the total amount is classified as a current liability within the Payables to affiliate - current line on the balance sheet. For the three and nine months ended March 31, 2022 , the Company recognized $ 0.1 million and $ 0.1 million, respectively, in the statement of operations related to services performed under the Advisory Agreement. For the three and nine months ended March 31, 2022 , $ 0.01 million and $ 0.1 million of costs incurred related to the performance of the Advisory Agreement services were included within research and development and $ 0.02 million and $ 0.06 million were included in general and administrative expense, respectively . For the three and nine months ended March 31, 2021 , the Company recognized $ 0.1 million and $ 0.9 million, respectively, in the condensed consolidated statements of operations related to services performed under the Advisory Agreement. For the three and nine months ended March 31, 2021 , $ 0.04 million and $ 0.4 million of costs incurred related to the performance of the Advisory Agreement services were included within research and development and $ 0.04 million and $ 0.2 million were included within general and administrative expense, respectively . In addition to the equity granted at formation, in May 2020 the Company and Mount Sinai each committed to making a loan to Kantaro. Mount Sinai committed to lend an initial amount of $ 0.3 million and an additional $ 0.5 million thereafter. The Company committed to lend an initial amount of $ 0.08 million and an additional $ 0.17 million thereafter. Each loan bears interest at a per year rate equal to 0.25 %, compounded monthly, until repaid, and is repayable from the first amounts that would otherwise constitute cash available for distribution to the members of Kantaro (provided that each loan repayment will be made, 75 % to Mount Sinai and 25 % to the Company based on each investor’s proportionate ownership). The Company loaned Kantaro $ 0.25 million and initially recorded a note receivable. The Company elected to recognize the equity investment losses based on the ownership level of each specific investment and will continue to record equity method losses until the amount of the loan receivable is reduced to zero. The loan had a carrying value of approximately $ 0.075 million at both March 31, 2022 and June 30, 2021. VericiDx During the three and nine months ended March 31, 2022, the Company paid the salary of an executive of VericiDx and VericiDx has agreed to reimburse the Company for those amounts. As of March 31, 2022, amounts due from VericiDx were recorded within the related party receivable line of the balance sheet and totaled less than one thousand dollars. As of March 31, 2021 , amounts due from VericiDx totaled $ 0.2 million.

Subsequent events

Subsequent events	9 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
Subsequent events	13. Subsequent events The Company has evaluated subsequent events from the condensed consolidated balance sheet date through the date at which the condensed consolidated financial statements were available to be issued, and determined there are no other items requiring disclosure beyond those disclosed below. In April 2022, the Company announced the successful completion of (i) an $ 8.8 million equity subscription (the "Equity Fundraise") and (ii) a subscription for convertible bonds with an aggregate principal amount of $ 21.2 million, raising aggregate gross proceeds of $ 26.8 million for the Company. The convertible bonds were issued at 85 % of the principal amount (resulting in net cash proceeds of $ 18.02 million, 5.5 % coupon (payable in cash or shares at the Company's option) and a 5 year term. The Equity Fundraise consisted of subscriptions for 2,221,794 Ordinary Shares ("New Ordinary Shares") and 103,447 American Depositary Shares (“ADSs”) (the "New ADS"), at a price of $ 7.25 per ADS (the "Reference ADS Price") or $ 3.625 per Ordinary Share, equivalent to approximately 276 pence per Ordinary Share.

Basis of presentation and sum_2

Basis of presentation and summary of significant accounting policies (Policies)	9 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Principles of consolidation	Principles of consolidation The unaudited interim condensed consolidated financial statements include the accounts of Renalytix plc, and its wholly-owned subsidiaries, Renalytix AI, Inc. and Renalytix AI Limited. All inter-company balances and transactions have been eliminated in consolidation. The Company accounts for investments in which it has significant influence but not a controlling financial interest using the equity method of accounting.
Use of estimates	Use of estimates The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the condensed consolidated financial statements, actual results may materially vary from these estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimate include the assumptions used in determining the fair value of share-based awards, recording the prepaid/accrual and associated expense for research and development activities performed for the Company by third parties, determining useful lives of property and equipment and capitalized software, the assessment of noncontrolling interest and equity method investments, fair value measurements (including those related to VericiDx), the payable to affiliates and the consolidation and deconsolidation of variable interest entities.
Segment information	Segment information The Company manages its operations as a single operating segment for the purposes of assessing performance and making operating decisions. The Company’s singular focus is to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Foreign currency	Foreign currency The Company’s condensed consolidated financial statements are presented in U.S. dollars, the reporting currency of the Company. The functional currency of Renalytix plc and Renalytix AI Limited is GB Pounds. The functional currency of Renalytix AI, Inc. is the U.S. dollar. Assets and liabilities of Renalytix plc and Renalytix AI Limited are translated at the rate of exchange at period-end, while the statements of operations are translated at the weighted average exchange rates in effect during the reporting period. The net effect of these translation adjustments is shown as a component of accumulated other comprehensive income. Transaction gains and losses resulting from exchange rate changes on transactions denominated in currencies other than the functional currency are included in income in the period in which the change occurs and reported in the consolidated statements of operations and comprehensive loss .
Concentrations of credit risk and major customers	Concentrations of credit risk and major customers Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable balances. Periodically, the Company maintains deposits in accredited financial institutions in excess of federally insured limits. The Company deposits its cash in financial institutions that it believes have high credit quality and are not exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships and has not experienced any losses on such accounts. The Company’s accounts receivable are derived from revenue earned from customers located in the U.S. All of the Company’s revenue has been generated from four customers for the nine months ended March 31, 2022, and two customer for the nine months ended March 31, 2021. The Company performs initial and ongoing credit reviews on customers, which involve consideration of the customers’ financial information, their location, and other factors to assess the customers’ ability to pay .
Fair value of financial instruments	Fair value of financial instruments At March 31, 2022 and June 30, 2021 , the Company’s financial instruments included accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. The carrying amounts of these assets and liabilities approximates fair value due to their short-term nature.
Fair value option	Fair value option Under the Fair Value Option Subsections of ASC subtopic 825-10, Financial Instruments – Overall , the Company has the irrevocable option to report most financial assets and financial liabilities at fair value on an instrument-by-instrument basis, with changes in fair value reported in earnings (see Note 5).
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments purchased with an original maturity of 90 days or less to be cash equivalents. As of March 31, 2022, the Company had a cash balance of $ 32.4 million. As of June 30, 2021, the Company had a cash balance of $ 65.1 million.
Accounts receivable	Accounts receivable Accounts receivable are recorded at the invoice amount and are non-interest bearing. The Company considers receivables past due based on the contractual payment terms. The Company reserves specific receivables if collectability is no longer reasonably assured. Estimates for allowances for doubtful accounts are determined based on existing contractual obligations, historical payment patterns, and individual customer circumstances. No reserves have been recorded as of March 31, 2022 or June 30, 2021 .
Property and equipment	Property and equipment Property and equipment are recorded at cost. Depreciation is determined using the straight-line method over the estimated useful lives ranging from three to ten years. Expenditures for maintenance and repairs are expensed as incurred while renewals and betterments are capitalized. When property and equipment are sold or otherwise disposed of, the cost and related accumulated depreciation are eliminated from the accounts and any resulting gain or loss is reflected in operations.
Performance of contract liability to affiliate	Performance of contract liability to affiliate In May 2020, the Company and the Icahn School of Medicine at Mount Sinai entered into an operating agreement (“Kantaro Operating Agreement”) to form a joint venture, Kantaro Biosciences LLC (“Kantaro”), for the purpose of developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2 originally developed by Mount Sinai. Kantaro has partnered with Bio-Techne Corporation to develop and launch the new test which is designed for use in any authorized clinical testing laboratory without the need for proprietary equipment. During the three and nine months ended March 31, 2022 , the Company recognized $ 0.03 million and $ 0.16 million, respectively, related to the performance of the contract liability with Kantaro. During the three and nine months ended March 31, 2021 , the Company recognized $ 0.13 million and $ 0.89 million, respectively, related to the performance of the contract liability with Kantaro. This represents the allocation of costs for performing services on behalf of Kantaro.
Equity method investment	Equity method investments The Company accounts for equity investments where it owns a non-controlling interest, but has the ability to exercise significant influence, under the equity method of accounting. Under the equity method of accounting, the original cost of the investment is adjusted for the Company’s share of equity in the earnings of the equity investee and reduced by dividends and distributions of capital received, unless the fair value option is elected, in which case the investment balance is marked to fair value each reporting period and the impact of changes in fair value of the equity investment are reported in earnings. Kantaro Biosciences LLC As the Company can exert significant influence over, but does not control, Kantaro’s operations through voting rights or representation on Kantaro’s board of directors, the Company accounts for this investment using the equity method of accounting. The Company records its share in Kantaro’s earnings and losses in the condensed consolidated statement of operations. The Company assesses its investment for other-than-temporary impairment when events or changes in circumstances indicate that the carrying amount of the investment might not be recoverable and recognize an impairment loss to adjust the investment to its then-current fair value. The Company owned 25 % of the membership equity units in Kantaro at March 31, 2022 and June 30, 2021. VericiDx Limited As the Company can exert significant influence over, but does not control, VericiDx’s operations through representation on VericiDx’s board of directors, the Company accounts for this investment as an equity method investment and has elected the fair value option because VericiDx’s stock price is readily observable via the London Stock Exchange. Under the fair value option, the investment in VericiDx is recorded at fair value at each reporting period with subsequent changes in fair value reported in the condensed consolidated statements of operations and comprehensive loss. Based on closing stock price of VericiDx, the fair value of the investment in VericiDx was $ 4.3 million at March 31, 2022 and $ 9.3 million at June 30, 2021. During the three and nine months ended March 31, 2022 , the Company recorded a fair value adjustment of $( 2.6 ) million and $( 4.6 ) million, respectively, in the condensed consolidated statements of operations and comprehensive loss. During each of the three and nine months ended March 31, 2021 , the Company recorded a fair value adjustment of $ 0.3 million and $ 5.4 million in the condensed consolidated statements of operations and comprehensive loss. The Company owned 5.8 % of the ordinary shares of VericiDx at March 31, 2022 and 6.9 % of the ordinary shares of VericiDx at June 30, 2021 .
Impairment assessment	Impairment assessment The Company evaluates its investments that are in unrealized loss positions, if any, and equity method investments for other-than-temporary impairment on a quarterly basis (see Note 5). Such evaluation involves a variety of considerations, including assessments of the risks and uncertainties associated with general economic conditions and distinct conditions affecting specific issuers or investees. Factors considered by the Company include (i) the length of time and the extent to which an investment’s fair value has been below its cost; (ii) the financial condition, credit worthiness, and near-term prospects of the issuer; (iii) the length of time to maturity; (iv) future economic conditions and market forecasts; (v) the Company’s intent and ability to retain its investment for a period of time sufficient to allow for recovery of market value; (vi) an assessment of whether it is more likely than not that the Company will be required to sell its investment before recovery of market value; and (vii) whether events or changes in circumstances indicate that the investment’s carrying amount might not be recoverable.
Software development costs	Software development costs The Company follows the provisions of ASC 985, Software, which requires software development costs for software to be marketed externally to be expensed as incurred until the establishment of technological feasibility, at which time those costs are capitalized until the software is available for general release and amortized over its estimated useful life of ten years. Technological feasibility is established upon the completion of a working model that has been validated. Revenue recognition The Company accounts for revenue under ASC 606 – Revenue from Contracts with Customers (“ASC 606”). Pursuant to ASC 606, the Company recognizes revenue when a customer obtains control of promised goods or services. The Company records the amount of revenue that reflects the consideration that it expects to receive in exchange for those goods or services. The Company applies the following five-step model in order to determine this amount: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. The Company only applies the five-step model to contracts when it is probable that it will collect the consideration to which it is entitled in exchange for the goods or services that it transfers to the customer. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations it must deliver and which of these performance obligations are distinct. Certain contracts have options for the customer to acquire additional services. The Company evaluates these options to determine if a material right exists. If, after that evaluation, it determines a material right does exist, it assigns value to the material right based upon the renewal option approach. The Company recognizes as revenue the amount of the transaction price that is allocated to each performance obligation when that performance obligation is satisfied or as it is satisfied. The Company uses present right to payment and customer acceptance as indicators to determine the transfer of control to the customer occurs at a point in time. Sales tax and other similar taxes are excluded from revenues .
Cost of revenue	Cost of revenue Cost of revenue consists of costs directly attributable to the services rendered, including labor costs and lab consumables directly related to revenue generating activities.
Research and development expenses	Research and development expenses Research and development costs consist primarily of costs incurred in connection with the development of KidneyIntelX and other studies for KidneyIntelX to determine clinical value and performance in different CKD populations. Research and development costs are expensed as incurred.
Income taxes	Share-based compensation The Company measures equity classified share-based awards granted to employees and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards over the requisite service period, which is the vesting period of the respective award. The Company accounts for forfeitures as they occur. For share-based awards with service-based vesting conditions, the Company recognizes compensation expense on a straight-line basis over the service period. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model, which requires inputs based on certain subjective assumptions, including the expected stock price volatility, the expected term of the option, the risk-free interest rate for a period that approximates the expected term of the option, and the Company’s expected dividend yield. The Company was a privately-held organization prior to November 2018 and has been a publicly-traded company for a limited period of time and therefore lacks company-specific historical and implied volatility information for its shares. Therefore, it estimates its expected share price volatility based on the historical volatility of publicly-traded peer companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded share price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is none based on the fact that the Company has never paid cash dividends on ordinary shares and does not expect to pay any cash dividends in the foreseeable future. The Company classifies share-based compensation expense in its condensed consolidated statement of operations and comprehensive loss in the same manner in which the award recipient’s payroll costs are classified or in which the award recipient’s service payments are classified.
Comprehensive loss	Comprehensive loss Comprehensive loss includes net loss as well as other changes in shareholders’ equity that result from transactions and economic events other than those with shareholders. For the periods presented the only other changes in shareholders’ equity is from foreign currency translation.
Net loss per ordinary share	Net loss per ordinary share Basic net loss per ordinary share is computed by dividing net loss by the weighted average number of ordinary shares outstanding during each period. Diluted net loss per ordinary share includes the effect, if any, from the potential exercise or conversion of securities, such as options which would result in the issuance of incremental ordinary shares. Potentially dilutive securities outstanding as of March 31, 2022 and 2021 have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive. Therefore, the weighted average number of shares used to calculate both basic and diluted net loss per share are the same. As of March 31, 2022 and 2021 , there were 4,560,901 and 3,683,858 shares, respectively, issuable upon exercise of outstanding options that were anti-dilutive and excluded from diluted loss per share for the three and nine months ended March 31, 2022 and 2021 , respectively.
Emerging growth company	Emerging growth company The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”). Under the JOBS Act, companies have extended transition periods available for complying with new or revised accounting standards. The Company has elected to avail itself of this exemption and, therefore, while the Company is an emerging growth company it will not be subject to new or revised accounting standards at the same time that they become applicable to other public emerging growth companies that have not elected to avail themselves of this exemption.
Recently issued accounting pronouncements	Recently issued accounting pronouncements In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) ("ASU 2016-02" or "Topic 842"), in order to increase transparency and comparability among organizations by, among other provisions, recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous U.S. GAAP. For public companies, ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. In transition, entities may also elect a package of practical expedients that must be applied in its entirety to all leases commencing before the adoption date, unless the lease is modified, and permits entities to not reassess (a) the existence of a lease, (b) the lease classification or (c) the determination of initial direct costs, as of the adoption date, which effectively allows entities to carryforward accounting conclusions under previous U.S. GAAP. In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements , which provides entities an optional transition method to apply the guidance under Topic 842 as of the adoption date, rather than as of the earliest period presented. In June 2020, the FASB issued ASU No 2020-05 that further delayed the effective date of Topic 842 to fiscal years beginning after July 1, 2022, and interim periods within those years. The Company is currently evaluating the impact of adopting this guidance to its condensed consolidated financial statements. In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments , which requires measurement and recognition of expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. This is different from the current guidance as this will require immediate recognition of estimated credit losses expected to occur over the remaining life of many financial assets. The new guidance will be effective for the Company on July 1, 2023. The Company is currently evaluating the impact of adopting this guidance to its consolidated financial statements. In January 2020, FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) ("ASU2021-01"), which, generally, provides guidance for investments in entities accounted for under the equity method of accounting. ASU 2020-01 is effective for all entities with fiscal years beginning after December 15, 2021, including interim periods therein. The Company is currently evaluating the impact of adopting this guidance to its consolidated financial statements.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Mar. 31, 2022
Revenue from Contract with Customer [Abstract]
Summarizes the Changes in Deferred Revenue	The following table summarizes the changes in deferred revenue: March 31, 2022 June 30, 2021 Balance, beginning of period $ 122 $ — Deferral of revenue 67 250 Revenue recognized ( 122 ) ( 128 ) Balance, end of period $ 67 $ 122

Fair value measurements and t_2

Fair value measurements and the fair value option (Tables)	9 Months Ended
	Mar. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets Measured on Recurring Basis	The following fair value hierarchy table presents information about the Company’s assets measured at fair value on a recurring basis: Fair value measurement at reporting date using (in thousands) (Level 1) (Level 2) (Level 3) March 31, 2022 Assets: Equity investment in VericiDx $ 4,322 $ — $ — June 30, 2021 Assets: Equity investment in VericiDx $ 9,295 $ — $ —

Property and equipment (Tables)

Property and equipment (Tables)	9 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property Plant and Equipment	Property and equipment consists of (in thousands): March 31, 2022 June 30, 2021 Lab equipment $ 1,144 $ 592 Software 1,574 1,534 Office equipment 121 84 Office furniture 35 35 Leasehold improvements 576 576 Construction in progress 79 — Total 3,529 2,821 Less accumulated depreciation and amortization ( 679 ) ( 331 ) $ 2,850 $ 2,490
Schedule of Expected Amortization Expense for the Next Five Years and Thereafter	As of March 31, 2022, the expected amortization expense for software for the next five years and thereafter is as follows: 2022 (remaining three months) $ 33 2023 130 2024 130 2025 130 2026 130 Thereafter 567 $ 1,120

Accrued expenses and other cu_2

Accrued expenses and other current liabilities (Tables)	9 Months Ended
	Mar. 31, 2022
Accounts Payable and Accrued Liabilities, Current [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of (in thousands): March 31, 2022 June 30, 2021 Consulting and professional fees $ 328 $ 954 Research and development 875 — Payroll and related benefits 4,701 3,493 Deferred offering 504 — Other 281 155 $ 6,689 $ 4,602

Commitments and contingencies (

Commitments and contingencies (Tables)	9 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of Commitments and Contingencies	The future minimum payments for noncancelable leases with terms in excess of one year for each fiscal year are as follows (in thousands): 2022 (remaining three months) $ 33 2023 134 2024 138 2025 46 2026 — Thereafter — Total $ 351

Share-based compensation (Table

Share-based compensation (Tables)	9 Months Ended
	Mar. 31, 2022
Share-based Payment Arrangement [Abstract]
Summary of total stock-based compensation expenses	The Company recorded share-based compensation expense in the following expense categories in the condensed consolidated statements of operations for the three and nine months ended March 31, 2022 and 2021 (in thousands): Three Months Ended March 31, Nine Months Ended March 31, 2022 2021 2022 2021 Research and development $ 78 $ 237 $ 378 $ 631 General and administrative 845 374 2,432 973 $ 923 $ 611 $ 2,810 $ 1,604
Summary of stock Option Pricing Model Assumption	For the nine months ended March 31, 2022 and 2021, the grant date fair value of all option grants was estimated at the time of grant using the Black-Scholes option-pricing model using the following weighted average assumptions: Nine Months Ended March 31, 2022 2021 Expected term (in years) 6.0 5.8 Expected volatility 65.77 % 67.10 % Risk-free rate 1.43 % 0.50 % Dividend yield — % — %
Summary of option activity	The following table summarizes the stock option granted to employees and non-employees for the nine months ended March 31, 2022: Number of Weighted- Weighted- Outstanding at June 30, 2021 4,265,958 $ 4.73 8.2 Granted 515,000 $ 10.06 Exercised ( 100,724 ) $ 1.89 Forfeited ( 119,333 ) $ 6.67 Outstanding at March 31, 2022 4,560,901 $ 4.99 8.7 Exercisable at March 31, 2022 3,213,850 $ 3.44 8.1 Vested at March 31, 2022 4,560,901 $ 4.99 8.7

Liquidity and Going Concern - A

Liquidity and Going Concern - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended
	Apr. 30, 2022	Mar. 31, 2022	Jun. 30, 2021
Going Concern [Line Items]
Retained earnings surplus deficit		$ (127,565)	$ (87,442)
Cash and cash equivalents		$ 32,361	$ 65,128
Gross proceeds	$ 26,800

Basis of presentation and sum_3

Basis of presentation and summary of significant accounting policies- Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021
Accounting Policies [Line Items]
Gain on Verici deconsolidation			$ 0		$ 46,000
Cash current	$ 32,400,000		32,400,000	$ 65,100,000
Cash equivalents current	32,361,000		32,361,000	65,128,000
Accounts receivable reserves recorded amount	0		0	$ 0
Kantaro Bio Sciences LLC [Member]
Accounting Policies [Line Items]
Performance of the contract liability	$ 30,000	$ 130,000	$ 160,000		890,000
Equity method investment ownership percentage	25%		25%	25%
Verici Dx Limited [Member]
Accounting Policies [Line Items]
Equity method investments fair value disclosure	$ 4,300,000		$ 4,300,000	$ 9,300,000
Fair value adjustment of investments	$ (2,600,000)	$ 300,000	$ (4,600,000)		$ 5,400,000
Percentage owned in the ordinary shares			5.80%	6.90%
Share-based Payment Arrangement, Option [Member]
Accounting Policies [Line Items]
Antidilutive securities excluded from the computation of earnings per share			4,560,901		3,683,858

Revenue - Additional Informatio

Revenue - Additional Information (Detail) - Transferred at Point in Time [Member] - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Testing Services Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue from contract with customer excluding assessed tax	$ 800,000	$ 100,000	$ 1,900,000	$ 100,000
Pharmaceutical Services Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue from contract with customer excluding assessed tax	0	0	200,000	400,000
Other Services Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue from contract with customer excluding assessed tax		$ 600,000		$ 600,000
Professional Services Revenue [Member]
Revenue From Contract With Customer [Line Items]
Revenue from contract with customer excluding assessed tax	$ 0		$ 0

Revenue - Summarizes the Change

Revenue - Summarizes the Changes in Deferred Revenue (Detail) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Revenue Recognition and Deferred Revenue [Abstract]
Balance, beginning of period	$ 122	$ 0
Deferral of revenue	67	250
Revenue recognized	(122)	(128)
Balance, end of period	$ 67	$ 122

Fair value measurements and t_3

Fair value measurements and the fair value option - Schedule of Fair Value of Assets Measured on Recurring Basis (Detail) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Level 1 [Member]
Assets, Fair Value Disclosure [Abstract]
Equity investment in VericiDx	$ 4,322	$ 9,295
Level 2 [Member]
Assets, Fair Value Disclosure [Abstract]
Equity investment in VericiDx	0	0
Level 3 [Member]
Assets, Fair Value Disclosure [Abstract]
Equity investment in VericiDx	$ 0	$ 0

Fair value measurements and t_4

Fair value measurements and the fair value option - Additional Information (Detail)	Mar. 31, 2022 USD ($)
Fair Value Disclosures [Abstract]
Fair value of equity method investment in Kantaro	$ 0

Property and equipment - Schedu

Property and equipment - Schedule of Property Plant and Equipment (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 3,529	$ 2,821
Less accumulated depreciation	(679)	(331)
Property, plant and equipment, net	2,850	2,490
Lab equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,144	592
Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	1,574	1,534
Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	121	84
Office Furniture [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	35	35
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	576	576
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 79	$ 0

Property and equipment - Additi

Property and equipment - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Depreciation Expense	$ 100	$ 50	$ 200	$ 100
Unamortized capitalized software development costs	1,100		1,100		$ 1,300
Amortization expense related to Capitalized software costs	$ 30	$ 30	$ 100	$ 50

Property and equipment - Sche_2

Property and equipment - Schedule of Expected Amortization Expense for the Next Five Years and Thereafter (Detail) $ in Thousands	Mar. 31, 2022 USD ($)
Property, Plant and Equipment [Abstract]
2022 (remaining three months)	$ 33
2023	130
2024	130
2025	130
2026	130
Thereafter	567
Amortization expense	$ 1,120

Accrued expenses and other cu_3

Accrued expenses and other current liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Detail) - USD ($) $ in Thousands	Mar. 31, 2022	Jun. 30, 2021
Consulting and professional fees	$ 328	$ 954
Research and development	875	0
Payroll and related benefits	4,701	3,493
Deferred offering	504	0
Other	281	155
Accrued expenses and other current liabilities	$ 6,689	$ 4,602

Commitments and contingencies -

Commitments and contingencies - Schedule of Commitments and Contingencies (Detail) $ in Thousands	Mar. 31, 2022 USD ($)
2022 (remaining three months)	$ 33
2023	134
2024	138
2025	46
2026	0
Thereafter	0
Future Minimum Payments	$ 351

Commitments and contingencies_2

Commitments and contingencies - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	Jan. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Rent expenses		$ 100,000	$ 100,000	$ 300,000	$ 300,000
Davita Inc [Member] | Master Care Coordination Services Agreement [Member]
Initial term of agreement				3 years
Renewal term				1 year
Monthly payment commitment for care coordination services multiplied by the number of covered patients	$ 10
Payment commitment for patient engagement services multiplied by the number of covered patients	$ 3.50
Maximum [Member]
Lease term		5 years		5 years
SafeHarborPlan [Member]
Defined benefit contribution percentage				5%
Defined benefit contribution amount		$ 100,000	$ 50,000	$ 300,000	$ 100,000

License and services agreemen_2

License and services agreements - Additional Information (Detail) - USD ($)		3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Disclosure Of License Agreements [Line Items]
Revenue		$ 812,000	$ 619,000	$ 2,139,000	$ 1,019,000
Research and development expenses		3,887,000	3,104,000	$ 12,019,000	7,311,000
Joslin License [Member]
Disclosure Of License Agreements [Line Items]
Royalty as a percentage of net sales				5%
Date of expiry of license agreement				Jul. 31, 2025
License agreement period of extension				5 years
License agreement period of notice to be given for termination of agreement				180 days
Accrued Royalties	$ 100,000	100,000		$ 100,000
Milestone Three [Member] | Joslin License [Member]
Disclosure Of License Agreements [Line Items]
Percentage of obligation on sublicense consideration received				25%
Milestone One [Member] | Joslin License [Member]
Disclosure Of License Agreements [Line Items]
Milestone payment payable	300,000	300,000		$ 300,000
Milestone One [Member] | Licensed Products [Member] | Joslin License [Member]
Disclosure Of License Agreements [Line Items]
Revenue				2,000,000
Milestone Two [Member] | Joslin License [Member]
Disclosure Of License Agreements [Line Items]
Milestone payment payable	1,000,000	1,000,000		1,000,000
Milestone Two [Member] | Licensed Products [Member] | Joslin License [Member]
Disclosure Of License Agreements [Line Items]
Revenue				10,000,000
Mount Sinai [Member]
Disclosure Of License Agreements [Line Items]
Estimated cost for carrying out of clinical study and fund upon approval of study protoal by the institutional review board				700,000
Mount Sinai [Member] | Mount Sinai COVID-19 sponsored research agreement [Member] | MASKeD-COVID Study [Mmeber]
Disclosure Of License Agreements [Line Items]
Amount obligated to pay for all direct and indirect costs incurred under agreement				1,800,000
Amount due to ISMMS under Study	1,000,000
Expensed amount		0	0	600,000	0
Mount Sinai [Member] | ISSMS And SRA [Member]
Disclosure Of License Agreements [Line Items]
Research and development expenses		0	$ 30,000	400,000	$ 300,000
Mount Sinai [Member] | Milestone One [Member] | ISSMS And SRA [Member]
Disclosure Of License Agreements [Line Items]
Milestone payment payable	1,500,000	1,500,000		1,500,000
Revenue				50,000,000
Mount Sinai [Member] | Milestone Two [Member] | ISSMS And SRA [Member]
Disclosure Of License Agreements [Line Items]
Milestone payment payable	$ 7,500,000	$ 7,500,000		7,500,000
Revenue				$ 300,000,000
Mount Sinai [Member] | Maximum [Member] | ISSMS And SRA [Member]
Disclosure Of License Agreements [Line Items]
Royalty as a percentage of net sales				5%
Expiration period from first commercial sale of product				12 years
Mount Sinai [Member] | Maximum [Member] | Milestone Three [Member] | ISSMS And SRA [Member]
Disclosure Of License Agreements [Line Items]
Percentage of obligation on sublicense consideration received				25%
Mount Sinai [Member] | Minimum [Member] | ISSMS And SRA [Member]
Disclosure Of License Agreements [Line Items]
Royalty as a percentage of net sales				4%
Mount Sinai [Member] | Minimum [Member] | Milestone Three [Member] | ISSMS And SRA [Member]
Disclosure Of License Agreements [Line Items]
Percentage of obligation on sublicense consideration received				15%

Shareholders' equity - Addition

Shareholders' equity - Additional Information (Detail) - USD ($)	9 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Stockholders' Equity Note [Abstract]
Common stock shares authorized	76,869,831	76,869,831
Cash dividends	$ 0

Share-based compensation - Addi

Share-based compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share based compensation weighted average fair value of the options granted			$ 10.06
share-based compensation expense	$ 923,000	$ 611	$ 2,810,000	$ 1,604
General and Administrative [Member]
share-based compensation expense	845,000	374	2,432,000	973
Research and Development [Member]
share-based compensation expense	78,000	237	$ 378,000	$ 631
Renalytix AI plc Share Option Plan [Member]
Share based Compensation options vested			80,724
Share based compensation weighted average fair value of the options granted			$ 6.02	$ 4.51
Unrecognized compensation expense related to stock options	8,100,000		$ 8,100,000
Unrecognized compensation expense related to stock options weighted average period			1 year 10 months 28 days
Share based compensation weighted aggregate intrinsic value of the options outstanding	4,400,000		$ 4,400,000
Share based compensation weighted aggregate intrinsic value of the options exercisable	$ 4,400,000		$ 4,400,000
Equity Incentive Plan [Member]
Common stock reserved for future issuance	2,642,062		2,642,062
Equity Incentive Plan [Member] | Restricted Stock [Member]
Share based Compensation options granted			1,077,100
Share based Compensation options granted percentage			25%
Share based Payment terms of award description			The options granted as of March 31, 2022 vest equally over twelve quarters following the grant date, with the exception of 80,724 options which vested immediately when granted, 1,077,100 options which vest 25% on the one year anniversary and equally over twelve quarters following the one year anniversary
Equity Incentive Plan [Member] | Restricted Stock [Member] | 1/12th on the one year anniversary [Member]
Share based Compensation options granted			500,000
Share based Compensation options granted percentage			0.08%
Employee Share Purchase Plan Member [Member]
Share based compensation,number of shares authorized for issuance	850,000		850,000
Share based compensation,purchase price of common stock at lower of the fair market value on the first day of offering period or purchase date percent			85%
Share based compensation,Employees may contribute upto their eligible compensation for purchase of common stock ,Percentage	15%		15%
Share based compensation,Purchase of Maximum number of shares worth of common stock for each calender year in which rights is outstanding			25,000
Share based compensation, number of shares purchased			10,920
Employee Share Purchase Plan Member [Member] | General and Administrative [Member]
share-based compensation expense	$ 200,000	$ 20,000	$ 70,000	$ 50,000
Employee Share Purchase Plan Member [Member] | Maximum [Member]
Share based compensation,increase in number of shares for a period			10 years
Employee Share Purchase Plan Member [Member] | Minimum [Member]
Increase in number of shares percentage of the total number of shares common stock outstanding during preceding calendar year End			1%
Share based compensation,Minimum number of shares to be added for each preceding calendar year end			2,000,000

Share-based compensation - Summ

Share-based compensation - Summary of Total Stock-based Compensation Expenses (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
share-based compensation expense	$ 923,000	$ 611	$ 2,810,000	$ 1,604
Research and Development [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
share-based compensation expense	78,000	237	378,000	631
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
share-based compensation expense	$ 845,000	$ 374	$ 2,432,000	$ 973

Share-based compensation - Su_2

Share-based compensation - Summary of Stock Option Pricing Model Assumption (Detail)	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (in years)	6 years	5 years 9 months 18 days
Expected volatility	65.77%	67.10%
Risk-free rate	1.43%	0.50%
Dividend yield	0%	0%

Share-based compensation - Su_3

Share-based compensation - Summary of Option Activity (Detail) - $ / shares	9 Months Ended	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
Number of shares under option plan, Beginning balance	4,265,958
Number of shares under option plan, Granted	515,000
Number of shares under option plan, Exercised	(100,724)
Number of shares under option plan, Forfeited	(119,333)
Number of shares under option plan, Ending balance	4,560,901	4,265,958
Number of shares under option plan, Exercisable at March 31, 2022	3,213,850
Number of shares under option plan, Vested and expected to vest at March 31, 2022	4,560,901
Weighted-average exercise price per option, Beginning balance	$ 4.73
Weighted-average exercise price per option, Granted	10.06
Weighted-average exercise price per option, Exercised	1.89
Weighted-average exercise price per option, Forfeited	6.67
Weighted-average exercise price per option, Ending balance	4.99	$ 4.73
Weighted-average exercise price per option, Exercisable at March 31, 2022	3.44
Weighted- average exercise price per option Vested and expected to vest at March 31, 2022	$ 4.99
Weighted- Average Remaining Contractual Life (years)	8 years 8 months 12 days	8 years 2 months 12 days
Weighted- average remaining contractual life Exercisable at March 31, 2022	8 years 1 month 6 days
Weighted- average remaining contractual life Vested and expected to vest at March 31, 2022	8 years 8 months 12 days

Related-party transactions - Ad

Related-party transactions - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2022	Mar. 31, 2021
Related Party Transaction [Line Items]
Equity method investments at fair value	$ 0			$ 0
Equity method investment net income loss	(26,000)	$ (8,000)		11,000	$ (229,000)
current liability	$ 15,037,000		$ 7,062,000	$ 15,037,000
Nontrade receivables		200,000			200,000
Loans and Leases Receivable	0.075		0.075
Capital Unit, Class A [Member] | Mount Sinai [Member]
Related Party Transaction [Line Items]
Equity method investment shares	750			750
Ekf Diagnostics [Member]
Related Party Transaction [Line Items]
Related party transaction expenses	$ 100,000	100,000		$ 200,000	100,000
Icahn School Of Medicine At Mount Shenai [Member]
Related Party Transaction [Line Items]
Related party transaction expenses	200,000	200,000		2,900,000	500,000
Amount due to related party	2,100,000			2,100,000
current liability	4,000,000			4,000,000
Kantaro Bio Sciences LLC [Member]
Related Party Transaction [Line Items]
Loan commitment to related party	$ 80,000			$ 80,000
Equity method investment ownership percentage	25%		25%	25%
Payment towards advances to related parties	$ 250,000
Carrying value of investment written down				$ 0
Equity investment	$ 4,000,000			4,000,000
Kantaro Bio Sciences LLC [Member] | Compounded Monthly [Member]
Related Party Transaction [Line Items]
Related party transaction interest rate	0.25%
Kantaro Bio Sciences LLC [Member] | Mount Sinai [Member]
Related Party Transaction [Line Items]
Loan commitment to related party	$ 300,000			300,000
Additional loan commitment to related party	$ 500,000			$ 500,000
Equity method investment ownership percentage	75%			75%
Kantaro Bio Sciences LLC [Member] | Advisory Agreement [Member]
Related Party Transaction [Line Items]
Period of service agreement with related party				5 years
Fair value of services to be provided to the related party	$ 200,000			$ 200,000
Due to affiliates	200,000			200,000
Recognised amount for services performed under agreement	100,000	100,000		100,000	900,000
Kantaro Bio Sciences LLC [Member] | Advisory Agreement [Member] | Valuation Technique, Discounted Cash Flow [Member] | Fair Value, Inputs, Level 3 [Member]
Related Party Transaction [Line Items]
Fair value of services to be provided to the related party	2,000,000			2,000,000
Due to affiliates	$ 2,000,000			$ 2,000,000
Kantaro Bio Sciences LLC [Member] | Advisory Agreement [Member] | Capital Unit, Class A [Member]
Related Party Transaction [Line Items]
Equity method investment shares	250			250
Kantaro Bio Sciences LLC [Member] | Advisory Agreement [Member] | Capital Unit, Class A [Member] | Valuation Technique, Discounted Cash Flow [Member] | Fair Value, Inputs, Level 3 [Member]
Related Party Transaction [Line Items]
Equity method investments at fair value	$ 2,000,000			$ 2,000,000
Kantaro Bio Sciences LLC [Member] | Commitment To Lend Additional Amount [Member]
Related Party Transaction [Line Items]
Additional loan commitment to related party	170,000			170,000
Kantaro Bio Sciences LLC [Member] | Research and Development [Member] | Advisory Agreement [Member]
Related Party Transaction [Line Items]
Costs incurred related to the performance of the services	10,000	40,000		100,000	400,000
Kantaro Bio Sciences LLC [Member] | General and Administrative [Member] | Advisory Agreement [Member]
Related Party Transaction [Line Items]
Costs incurred related to the performance of the services	$ 20,000	$ 40,000		$ 60,000	$ 200,000

Subsequent events - (Additional

Subsequent events - (Additional Information) (Details) - 1 months ended Apr. 30, 2022 $ / shares in Units, $ in Thousands	USD ($) $ / shares shares	£ / shares
Subsequent Event [Line Items]
Stock issued during the period, Value	$ 8,800
Aggregate principal amount of convertible bonds	$ 21,200
Percentage of principal amount issued of convertible debt	85%
Gross proceeds	$ 26,800
Cash proceeds from convertible notes payable	$ 18,020
Coupon rate	5.50%
Long term debt term	5 years
Stock issued | shares	2,221,794
Shares issued, price per share | (per share)	$ 3.625	£ 276
American Depositary Shares [Member]
Subsequent Event [Line Items]
Stock issued | shares	103,447
Shares issued, price per share | $ / shares	$ 7.25